Pilot Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
More than 29 million people in the US are living with diabetes, many of whom will develop diabetic retinopathy (DR) or diabetic eye disease (DED), the leading cause of vision loss and blindness in working-age adults. Annual eye screening is recommended for all diabetic patients since vision loss can be prevented with laser photocoagulation and anti-VEGF injections if DR is diagnosed in its early stages. Currently, the number of clinical personnel trained for DR screening is orders of magnitude smaller than that needed to screen the large, growing diabetic population. Therefore, to meet this large unmet need for DR screening, a fully-automated computerized DR screening system is necessary. This study is designed to assess the performance of EyeArt, an automated DR screening tool.
Condition or disease
Procedure: Color fundus photographyDrug: Mydriatic Agent
Number of subjects whose EyeArt results match the reading center grading for identifying referable diabetic eye disease (moderate NPDR or higher on the ICDR scale or surrogate markers for CSME). [ Time Frame: 1 visit ]
The performance of EyeArt will be evaluated using overall accuracy, sensitivity, and specificity measures.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
The study subjects will be enrolled at a primary care center
18 years of age or older;
a diagnosis of diabetes mellitus; and
understanding of study and provision of written informed consent.
Persistent visual impairment or sudden vision loss in one or both eyes;
History of uncorrected media opacity in one or both eyes;
History of retinal vascular disease other than diabetic eye disease;
History of ocular injections, laser treatment of the retina, or intraocular surgery other than cataract;
Subject has contraindications for mydriatic medications or is unwilling or unable to dilate;
Subject is currently enrolled in an interventional study of an investigational device/drug; or
Subject has a condition or is in a situation which in the opinion of the Investigator, might confound study results, may interfere significantly with the subject's participation in the study, or result in ungradable 4-wide field stereoscopic mydriatic fundus photographs.